CD274 and neoplasm: The US FDA‐approved antibodies blocking the PD‐L1/PD‐1 axis are cemiplimab, nivolumab, pembrolizumab, atezolizumab, avelumab, and durvalumab.[132, 133, 134] However, there are limitations to using this treatment, and the tumor can become resistant to anti‐inhibitory molecules.